Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01706471
Recruitment Status : Completed
First Posted : October 15, 2012
Last Update Posted : February 19, 2014
Information provided by (Responsible Party):
Yonsei University

Brief Summary:

Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients. Although marked progression has been made in initial survival rates, long-term kidney graft survival has yet to show such encouraging results. Because CNIs are associated with adverse effects, particularly nephrotoxicity, which contribute to declining organ function and eventual graft loss. In kidney transplants, progressive allograft dysfunction has been shown to develop in as many as 94% of patients by 1 year.

Therefore, reducing or eliminating the dose of CNIs to minimize nephrotoxicity must be balanced against the maintenance of adequate immunosuppression.

Certican allows CNI dose reduction then provides renal function improvement and current PSI strategy point out that early intervention is important in managing the risk of CAN before it develops in both de novo and maintenance renal transplant recipients.

To demonstrate Certican early introduction after 1 month provides better renal function with no change of efficacy compared to standard regimen, and also prevent delayed wound healing.

Condition or disease Intervention/treatment Phase
Planned Kidney Transplantation Drug: Everolimus + Low dose CsA +PD Drug: Myfortic+ Standard CsA + PD Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : June 2009
Primary Completion Date : January 2013
Study Completion Date : April 2013

Arm Intervention/treatment
Experimental: Everolimus + Low dose CsA +PD Drug: Everolimus + Low dose CsA +PD
Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
Active Comparator: Myfortic+ Standard CsA + PD Drug: Myfortic+ Standard CsA + PD
Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.

Primary Outcome Measures :
  1. Reduced Exposure Cyclosporine in Renal Transplant Recipients [ Time Frame: 12 months after the time of kidney transplantation ]
    A 12-month, multi center, randomized, open-label, non-inferiority study of efficacy and safety comparing early introduction of Certican® after 1 month and standard regimen in de novo renal transplant recipients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or Females aged 18~65 years
  2. De novo recipients of cadaveric, living unrelated or living related donor kidney transplants
  3. Received kidney transplant from aged 10~65years donor
  4. Willing to provide written informed consent
  5. Completing study visits according to study protocol

Exclusion Criteria:

  1. Recipients of multiple organ transplants
  2. Kidney transplant from non-heart beating cadaveric donor / organ donor after cardiac death
  3. Recipients of A-B-O incompatible transplants or lymphocyte cross-match positive transplants
  4. Recipients of extra-renal solid organ transplants or stem cell transplants
  5. Recipient/ donor who are known to have anti-HCV, HIV or HBsAg positive
  6. Diagnosed as Cancer within the past 5 years (except complete recovered squamous cell or basal cell skin cancer)
  7. Drug Hypersensitivity to investigational drugs or related drugs Females are pregnant and lactating
  8. Any of the following laboratory abnormalities at screening:

    • ALT, AST, ALP, total bilirubin > 3 times the upper limit
    • ANC < 1,500mm3 or WBC < 2,500mm3 or platelet < 100,000 mm3
    • Cholesterol > 350 mg/dl or 9.0 mmol/L, TG > 500 mg/dl or 5.6mmol/L

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01706471

Korea, Republic of
Department of Surgery, Yonsei University College of Medicine, Severance Hospital
Seoul, Korea, Republic of, 120-752
Sponsors and Collaborators
Yonsei University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yonsei University Identifier: NCT01706471     History of Changes
Other Study ID Numbers: 4-2009-0109
First Posted: October 15, 2012    Key Record Dates
Last Update Posted: February 19, 2014
Last Verified: February 2014

Keywords provided by Yonsei University:

Additional relevant MeSH terms:
Mycophenolic Acid
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action